Use of different formulations of hormonal contraceptives for female adolescents aged 12–18 years in general practices in the UK
| Aged 12–15 years Patients [n (%)] | Aged 16–18 years Patients [n (%)] | |||
|---|---|---|---|---|
| Formulations* | 2002 | 2011 | 2002 | 2011 |
| Total number of patients with hormonal contraceptive prescriptions | 794 | 968 | 5341 | 5629 |
| Combined oral contraceptive (progestogen+estrogen): | ||||
| Ethinylestradiol+levonorgestrel | 492 (62.0) | 560 (57.9) | 3385 (63.4) | 3053 (54.2) |
| Ethinylestradiol+drospirenone | 13 (1.6) | 62 (6.4) | 68 (1.3) | 566 (10.1) |
| Ethinylestradiol+norgestimate | 68 (8.6) | 59 (6.1) | 615 (11.5) | 436 (7.7) |
| Ethinylestradiol+norethisterone | 101 (12.7) | 75 (7.7) | 437 (8.2) | 309 (5.5) |
| Ethinylestradiol+desogestrel | 28 (3.5) | 47 (4.9) | 259 (4.8) | 345 (6.1) |
| Ethinylestradiol+gestodene | 23 (2.9) | 16 (1.7) | 199 (3.7) | 125 (2.2) |
| Progestogen-only contraceptive: | ||||
| Desogestrel | 0 (0.0) | 100 (10.3) | 0 (0.0) | 767 (13.6) |
| Etonogestrel (implant) | 2 (0.3) | 91 (9.4) | 19 (0.4) | 380 (6.8) |
| Levonorgestrel | 155 (19.5) | 64 (6.6) | 740 (13.9) | 308 (5.5) |
| Depot medroxyprogesterone acetate | 37 (4.7) | 57 (5.9) | 496 (9.3) | 474 (8.4) |
Data are presented as number and percentage of patients [n (%)]. The percentages in the table do not add up to 100% as a patient might be prescribed more than one formulation of contraceptive during a year.
*All formulations presented in the table are oral form unless otherwise specified.